Effects of Interventions to Prevent Work-Related Asthma, Allergy, and Other Hypersensitivity Reactions in Norwegian Salmon Industry Workers (SHInE): Protocol for a Pragmatic Allocated Intervention Trial and Related Substudies.
allergy
bioaerosols
exposure-response
health promotion
hypersensitivity
occupational asthma
occupational skin disease
psychosocial work environment
salmon processing industry
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
19 Jul 2023
19 Jul 2023
Historique:
received:
07
05
2023
accepted:
30
05
2023
medline:
19
7
2023
pubmed:
19
7
2023
entrez:
19
7
2023
Statut:
epublish
Résumé
Workers in the salmon processing industry have an increased risk of developing respiratory diseases and other hypersensitivity responses due to occupational exposure to bioaerosols containing fish proteins and microorganisms, and related allergens. Little is known about effective measures to reduce bioaerosol exposure and about the extent of skin complaints among workers. In addition, while identification of risk factors is a core activity in disease prevention strategies, there is increasing interest in health-promoting factors, which is an understudied area in the salmon processing industry. The overall aim of this ongoing study is to generate knowledge that can be used in tailored prevention of development or chronification of respiratory diseases, skin reactions, protein contact dermatitis, and allergy among salmon processing workers. The main objective is to identify effective methods to reduce bioaerosol exposure. Further objectives are to identify and characterize clinically relevant exposure agents, identify determinants of exposure, measure prevalence of work-related symptoms and disease, and identify health-promoting factors of the psychosocial work environment. Data are collected during field studies in 9 salmon processing plants along the Norwegian coastline. Data collection comprises exposure measurements, health examinations, and questionnaires. A wide range of laboratory analyses will be used for further analysis and characterization of exposure agents. Suitable statistical analysis will be applied to the various outcomes of this comprehensive study. Data collection started in September 2021 and was anticipated to be completed by March 2023, but was delayed due to the COVID-19 pandemic. Baseline data from all 9 plants included 673 participants for the health examinations and a total of 869 personal exposure measurements. A total of 740 workers answered the study's main questionnaire on demographics, job characteristics, lifestyle, health, and health-promoting factors. Follow-up data collection is not completed yet. This study will contribute to filling knowledge gaps concerning salmon workers' work environment. This includes effective workplace measures for bioaerosol exposure reduction, increased knowledge on hypersensitivity, allergy, respiratory and dermal health, as well as health-promoting workplace factors. Together this will give a basis for improving the work environment, preventing occupational health-related diseases, and developing occupational exposure limits, which in turn will benefit employees, employers, occupational health services, researchers, clinicians, decision makers, and other stakeholders. ClinicalTrials.gov NCT05039229; https://www.clinicaltrials.gov/study/NCT05039229. DERR1-10.2196/48790.
Sections du résumé
BACKGROUND
BACKGROUND
Workers in the salmon processing industry have an increased risk of developing respiratory diseases and other hypersensitivity responses due to occupational exposure to bioaerosols containing fish proteins and microorganisms, and related allergens. Little is known about effective measures to reduce bioaerosol exposure and about the extent of skin complaints among workers. In addition, while identification of risk factors is a core activity in disease prevention strategies, there is increasing interest in health-promoting factors, which is an understudied area in the salmon processing industry.
OBJECTIVE
OBJECTIVE
The overall aim of this ongoing study is to generate knowledge that can be used in tailored prevention of development or chronification of respiratory diseases, skin reactions, protein contact dermatitis, and allergy among salmon processing workers. The main objective is to identify effective methods to reduce bioaerosol exposure. Further objectives are to identify and characterize clinically relevant exposure agents, identify determinants of exposure, measure prevalence of work-related symptoms and disease, and identify health-promoting factors of the psychosocial work environment.
METHODS
METHODS
Data are collected during field studies in 9 salmon processing plants along the Norwegian coastline. Data collection comprises exposure measurements, health examinations, and questionnaires. A wide range of laboratory analyses will be used for further analysis and characterization of exposure agents. Suitable statistical analysis will be applied to the various outcomes of this comprehensive study.
RESULTS
RESULTS
Data collection started in September 2021 and was anticipated to be completed by March 2023, but was delayed due to the COVID-19 pandemic. Baseline data from all 9 plants included 673 participants for the health examinations and a total of 869 personal exposure measurements. A total of 740 workers answered the study's main questionnaire on demographics, job characteristics, lifestyle, health, and health-promoting factors. Follow-up data collection is not completed yet.
CONCLUSIONS
CONCLUSIONS
This study will contribute to filling knowledge gaps concerning salmon workers' work environment. This includes effective workplace measures for bioaerosol exposure reduction, increased knowledge on hypersensitivity, allergy, respiratory and dermal health, as well as health-promoting workplace factors. Together this will give a basis for improving the work environment, preventing occupational health-related diseases, and developing occupational exposure limits, which in turn will benefit employees, employers, occupational health services, researchers, clinicians, decision makers, and other stakeholders.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov NCT05039229; https://www.clinicaltrials.gov/study/NCT05039229.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
DERR1-10.2196/48790.
Identifiants
pubmed: 37467018
pii: v12i1e48790
doi: 10.2196/48790
pmc: PMC10398556
doi:
Banques de données
ClinicalTrials.gov
['NCT05039229']
Types de publication
Journal Article
Langues
eng
Pagination
e48790Informations de copyright
©Anje Christina Höper, Jorunn Kirkeleit, Marte Renate Thomassen, Kaja Irgens-Hansen, Bjørg Eli Hollund, Carl Fredrik Fagernæs, Sindre Rabben Svedahl, Thor Eirik Eriksen, Miriam Grgic, Berit Elisabeth Bang. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 19.07.2023.
Références
Genet Med. 2012 Apr;14(4):361-84
pubmed: 22436882
J Occup Environ Med. 2010 Dec;52(12):1167-72
pubmed: 21124247
Ann Work Expo Health. 2018 Oct 15;62(8):942-952
pubmed: 29947734
Am J Ind Med. 2014 Mar;57(3):276-85
pubmed: 24310925
Water Res. 2023 Mar 1;231:119625
pubmed: 36680819
Curr Allergy Asthma Rep. 2013 Jun;13(3):288-97
pubmed: 23575656
Occup Environ Med. 2001 Sep;58(9):553-62
pubmed: 11511741
J Allergy Clin Immunol. 1997 Jul;100(1):16-22
pubmed: 9257782
Chest. 1993 Aug;104(2):600-8
pubmed: 7802735
Allergy. 2016 Jun;71(6):765-79
pubmed: 26913451
Am J Ind Med. 2012 Jul;55(7):624-30
pubmed: 22576678
Contact Dermatitis. 1989 Sep;21(3):172-8
pubmed: 2791541
Contact Dermatitis. 2005 Feb;52(2):102-7
pubmed: 15725289
Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88
pubmed: 31613151
Br J Dermatol. 2005 Feb;152(2):302-7
pubmed: 15727643
Biology (Basel). 2020 Aug 25;9(9):
pubmed: 32854310
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Thorax. 1996 May;51(5):484-9
pubmed: 8711675
ERJ Open Res. 2018 Oct 03;4(4):
pubmed: 30302334
Work. 2010;35(2):153-61
pubmed: 20164610
Allergy. 2019 Oct;74(10):1852-1871
pubmed: 30953601
Lancet. 1995 Sep 16;346(8977):737-40
pubmed: 7658875
J Agromedicine. 2019 Oct;24(4):441-448
pubmed: 31453763
Scand J Public Health. 2018 Nov;46(7):711-717
pubmed: 28825350
Ann Work Expo Health. 2020 Oct 8;64(8):817-825
pubmed: 32491156
Work. 2013;45(3):379-87
pubmed: 23324702
J Occup Environ Med. 2005 May;47(5):482-92
pubmed: 15891527
Trends Biotechnol. 2001 Aug;19(8):277-81
pubmed: 11451451
Curr Opin Allergy Clin Immunol. 2010 Apr;10(2):104-13
pubmed: 20179585
Thorax. 2007 Feb;62(2):147-52
pubmed: 17040933
Genome Med. 2019 May 23;11(1):31
pubmed: 31122281
Front Allergy. 2021 Oct 08;2:747011
pubmed: 35387025
Anal Biochem. 1985 Oct;150(1):76-85
pubmed: 3843705
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Saf Health Work. 2014 Dec;5(4):175-80
pubmed: 25516808
Ann Epidemiol. 2007 Sep;17(9):643-53
pubmed: 17553702